Tumor-related prognostic factors for breast cancer

Ca-A Cancer Journal for Clinicians

Volumn 47, Issue 1, 1997, Pages 28-51

  Donegan, William L ^a,b  

^a AURORA SINAI MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN D; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; PROTEINASE; STEROID RECEPTOR;

ADULT; AGE; AGED; ANGIOGENESIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CELL CYCLE S PHASE; FEMALE; HUMAN; HUMAN CELL; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MITOSIS INDEX; MULTIVARIATE ANALYSIS; PLOIDY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE; REVIEW; SURVIVAL TIME; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

EID: 0031031582     PISSN: 00079235     EISSN: None     Source Type: Journal    
DOI: 10.3322/canjclin.47.1.28     Document Type: Review

References (174)

1. Osborne CK: Prognostic factors in breast cancer. Principles & Practice of Oncology PPO Updates 1990;4:1-11.
2. Mittra I. MacRae KD: A meta-analysis of reported correlations between prognostic factors in breast cancer: Does axillary lymph node metastasis represent biology or chronology? Eur J Cancer 1991; 27:1574-1583.
3. Yoshimoto M, Sakamoto G, Ohashi Y: Time dependency of the influence of prognostic factors on relapse in breast cancer. Cancer 1993;72:2993-3001.
4. Hacene K,LeDoussal V, Rouesse J, Brunet M: Predicting distant metastases in operable breast cancer patients. Cancer 1990;66:2034-2043.
5. Figueroa JA, Yee D, McGuire WL: Prognostic indicators in early breast cancer. Am J Med Sci 1993;305:176-182.
6. Bullock C: With computer, MDs can predict risk of relapse in breast ca. Oncology Times 1988;10:1, 37.
7. Ravdin PM, Clark GM: A practical application of neural network analysis for predicting outcome of individual breast cancer patients. Breast Cancer Res Treat 1992;22:285-293.
8. McGuire WL, Tandon AK, Allred DC, et al: How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 1990;82:1006-1015.
9. Berg JW, Hutter RV: Breast Cancer. Cancer 1995;75:257-269.
10. Silverstein MJ, Poller DN, Waisman JR, et al: Prognostic classification of breast ductal carcinoma- in-situ. Lancet 1995;345:1154-1157.
11. Fisher ER, Costantino J, Fisher B, et al: Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17: Intraductal carcinoma (ductal carcinoma in situ). Cancer 1995;75:1310-1319.
12. Wong JH, Kopald KH, Morton DL: The impact of microinvasion on axillary node metastases and survival in patients with intraductal breast cancer. Arch Surg 1990;125:1298-1302.
13. Silverstein MJ, Gierson ED, Waisman JR, et al: Axillary lymph node dissection for T1a breast carcinoma: Is it indicated? Cancer 1994;73:664-667.
14. Nemoto T, Vana J, Bedwani RN, et al: Management and survival of female breast cancer: Results of a national survey by the American College of Surgeons. Cancer 1980;45:2917-2924.
15. Carter CL, Allen C, Henson DR: Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181-187.
16. Donegan WL: Staging and primary treatment, in Donegan WL, Spratt JS (eds): Cancer of the Breast, ed 4. Philadelphia, WB Saunders, 1995, p. 392.
17. Komaki K, Sakamoto G, Sugano H, et al: Mucinous carcinoma of the breast in Japan: A prognostic analysis based on morphologic features. Cancer 1988;61:989-996.
18. Silverberg SG, Kay S, Chitale AR, Levitt SH: Colloid carcinoma of the breast. Am J Clin Pathol 1971;55:355-363.
19. Carstens PH, Huvos AG, Foote FW Jr, Ashikari R: Tubular carcinoma of the breast: A clinico-pathologic study of 35 cases. Am J Clin Pathol 1972;58:231-238.
20. Meters GN, Wolff M, Haagensen CD: Tubular carcinoma of the breast: Clinical pathologic correlations based on 100 cases. Ann Surg 1981;193:138-149.
21. Carter D, Orr SL, Merino MJ: Intracystic: papillary carcinoma of the breast: After mastectomy, radiotherapy, or excisional biopsy alone. Cancer 1983;52:14-19.
22. Rapin V, Contesso G, Mouriesse H, et al: Medullary breast carcinoma: A reevaluation of 95 cases of breast cancer with inflammatory stroma. Cancer 1988;61:2503-2510.
23. Fisher ER, Kenny JP, Sass R, et al: Medullary cancer of the breast revisited. Breast Cancer Res Treat 1990;16:215-229.
24. Garne JP, Aspegren K, Linell F, et al: Primary prognostic factors in invasive breast cancer with special reference to ductal carcinoma and histologic malignancy grade. Cancer 1994;73:1438-1448.
25. Rosen PR, Groshen S, Saigo PE, et al: A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 1989;7:355-366.
26. Rosen PP, Groshen S, Kinne DW, Norton L: Factors influencing prognosis in node-negative breast carcinoma: Analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol 1993;11:2090-2100.
27. Lee AK, DeLellis RA, Silverman ML, et al: Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. J Clin Oncol 1990;8:1457-1465.
28. Clemente CG, Boracchi P, Andreola S, et al: Peritumoral lymphatic invasion in patients with node-negative mammary duct carcinoma. Cancer 1992;69:1396-1403.
29. Fisher ER, Anderson S, Redmond C, Fisher B: Pathologic findings from the National Surgical Adjuvant Breast Project Protocol B-06: 10-year pathologic and clinical prognostic discriminants. Cancer 1993;71:2507-2514.
30. Rosen PP, Groshen S: Factors influencing survival and prognosis in early breast carcinoma (T1N0M0-T1N1M0): Assessment of 644 patients with median follow-up of 18 years. Surg Clin North Am 1990;70:937-962.
31. Davis BW, Gelber RD, Goldhirsch A, et al: Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer 1986; 58:2662-2670.
32. Contesso G, Mouriesse H, Friedman S, et al: The importance of histologic grade in long-term prognosis of breast cancer: A study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy. J Clin Oncol 1987;5:1378-1386.
33. Fisher ER, Redmond C, Fisher B: Histologic grading of breast cancer. Pathol Annu 1980;15:239-251.
34. Elston CW: Grading of invasive carcinoma of the breast, in Page DL. Anderson TJ (eds): Diagnostic Histopathology of the Breast. New York, Churchill Livingstone, 1990, pp 300-311.
35. Winchester DJ, Duda RB, August CZ, et al: The importance of DNA flow cytometry in node-negative breast cancer. Arch Surg 1990;125:886-889.
36. Henson DE, Ries L, Freedman LS, Carriaga M: Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. Cancer 1991;68:2142-2149.
37. Fisher ER, Costantino J, Fisher B, Redmond C: Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol 4). Cancer 1993;71:2141-2150.
38. Shek LL, Godolphin W: Model for breast cancer survival: Relative prognostic roles of axillary nodal status, TNM stage, estrogen receptor concentration, and tumor necrosis. Cancer Res 1988;48:5565-5569.
39. Stierer M, Rosen HR, Weber R, et al: Long term analysis of factors influencing the outcome in carcinoma of the breast smaller than one centimeter. Surg Gynecol Obstet 1992;175:151-160.
40. Fisher B, Fisher ER, Redmond C, Brown A: Tumor nuclear grade, estrogen receptor, and progesterone receptor: Their value alone or in combination as indicators of outcome following adjuvant therapy for breast cancer. Breast Cancer Res Treat 1986;7:147-160.
41. Fisher B, Redmond C, Fisher ER, Caplan R: Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node-negative breast cancer patients: Findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 1988;6:1076-1087.
42. Gilchrist KW, Kalish L, Gould VE, et al: Interobserver reproducihility of histopathological features in stage II breast cancer. Breast Cancer Res Treat 1985;5:3-10.
43. Gresham GA: Grading of mammary carcinoma. Clin Oncol 1976;2:351-356.
44. Ravdin PM: A practical view of prognostic factors for staging, adjuvant treatment planning, and as baseline studies for possible future therapy. Hematol Oncol Clin North Am 1994;8:197-211.
45. Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991; 324:1-8.
46. Van Hoef ME, Knox WF, Dhesi SS, et al: Assessment of tumor vascularity as a prognostic factor in lymph node negative invasive breast cancer. Eur J Cancer 1993;29A:1141-1145.
47. Toi M, Kashitani J, Tominaga T: Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 1993; 55:371-374.
48. Khanuja PS, Gimotty P, Fregene T, et al: Angiogenesis quantilation as a prognostic factor for primary breast carcinoma 2 cms or less, in Salmon SE (ed): Adjuvant Therapy of Cancer VII. Philadelphia, JB Lippincott Co, 1993, pp 226-232.
49. Axelsson K, Ljung BM, Moore DH 2nd, et al: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 1995;87:997-1008.
50. Layfield LJ, Chrischilles EA, Cohen MB. Boules K: The palpable breast nodule: A cost-effectiveness analysis of alternate diagnostic approaches. Cancer 1993;72:1642-1651.
51. Axtell LM, Cutler SJ, Myers MH (eds): End Results in Cancer Report No. 4. [DHEW Publication No. (NIH) 73-272]. Bethesda. Md. National Cancer Institute. 1972, p 101.
52. Gardner B, Feldman J: Are positive axillary nodes in breast cancer markers for incurable disease? Ann Surg 1993;218:270-278.
53. Beahrs OH, Henson EH, Mutter RVP, Kennedy BJ (eds): Manual for Staging of Cancer, ed 4. Philadelphia, JB Lippincott Co. 1992:149-154.
54. Veronesi U, Cascinelli N, Greco M, et al: Prognosis of breast cancer patients after mastectomy and dissection of internal mammary nodes. Ann Surg 1985;202:702-707.
55. Donegan WL: Mastectomy in the primary management of invasive mammary carcinoma, in Hardy JD (ed): Advances in Surgery, Vol. 6. Chicago, Year Book Medical Publishers Inc. 1972, pp 1-101.
56. Fisher B, Wolmark N, Bauer M, et al: The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet 1981;152:765-772.
57. Fisher B: Some thoughts concerning the primary therapy of breast cancer. Recent Results Cancer Res 1976;57:150-163.
58. Cody HS 3rd. Egeli RA, Urban JA: Rotter's node metastases: Therapeutic and prognostic considerations in early breast carcinoma. Ann Surg 1984;199:266-270.
59. Yang JH, Slack NH, Nemoto T: Effect of axillary nodal status on the long-term survival following mastectomy for breast carcinoma: Nodal metastases may not always suggest systemic disease. J Surg Oncol 1987;36:243-248.
60. Wilson RE, Donegan WL, Mettlin C, et al: The 1982 national survey of carcinoma of the breast in the United States by the American College of Surgeons. Surg Gynecol Obstet 1984;159:309-318.
61. Russo J, Frederick J, Ownby HE, et al: Predictors of recurrence and survival of patients with breast cancer. Am J Clin Pathol 1987:88:123-131.
62. Smith JA 3rd. Gamez-Araujo JJ, Gallager HS, et al: Carcinoma of the breast: Analysis of total lymph node involvement versus level of metastasis. Cancer 1977;39:527-532.
63. Donegan WL: Prognostic factors: Stage and receptor status in breast cancer. Cancer 1992; 70:1755-1764.
64. Boova RS, Bonanni R, Rosato FE: Patterns of axillary nodal involvement in breast cancer: Predictability of level one dissection. Ann Surg 1982;196:642-644.
65. Mambo NC, Gallager HS: Carcinoma of the breast: The prognostic significance of extranodal extension of axillary disease. Cancer 1977;39:2280-2285.
66. Donegan WL, Stine SB, Samter TG: Implications of extracapsular nodal metastases for treatment and prognosis of breast cancer. Cancer 1993;72:778-782.
67. Barth RJ Jr. Danforth DN Jr. Venzon DJ, et al: Level of axillary involvement by lymph node metastases from breast cancer is not an independent predictor of survival. Arch Surg 1991;126:574-577.
68. Rosen PP, Saigo PE, Braun DW, et al: Axillary micro- and macrometastases in breast cancer: Prognostic significance of tumor size. Ann Surg 1981;194:585-591.
69. Huvos AG, Hutler RVP, Berg JW: Significance of axillary macrometastases and micrometastases in mammary cancer. Ann Surg 1971;173:44-46.
70. Clayton F, Hopkins CL: Pathologic correlates of prognosis in lymph node-positive breast carcinomas. Cancer 1993;71:1780-1790.
71. Wilkinson EJ, Hause LL, Hoffman RG, et al: Occult axillary lymph node metastases in invasive breast carcinoma: Characteristics of the primary tumor and significance of the metastases. Pathol Annu 1982;17:67-91.
72. Fisher ER, Palekar A, Rockette H, et al: Pathologic findings from the National Surgical Adjuvant Breast Project. (Protocol No. 4). V. Significance of axillary nodal micro- and macrometastases. Cancer 1978;42:2032-2038.
73. International (Ludwig) Breast Cancer Study Group: Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet 1990;335:1565-1568.
74. Noguchi S, Aihara T, Nakamori S, et al: The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Cancer 1994;74: 1595-1600.
75. Osborne MP, Rosen PP: Detection and management of bone marrow micrometastases in breast cancer. Oncology 1994;8:25-31.
76. Noguchi M, Koyasaki N, Ohta N, et al: Internal mammary nodal status is a more reliable prognostic factor than DNA ploidy and c-erb B-2 expression in patients with breast cancer. Arch Surg 1993; 128:242-246.
77. Noguchi M, Ohta N, Koyasaki N, et al: Reappraisal of internal mammary node metastases as a prognostic factor in patients with breast cancer. Cancer 1991;68:1918-1925.
78. Fentiman IS, Lavelle MA, Caplan D, et al: The significance of supraclavicular fossa node recurrence after radical mastectomy. Cancer 1986;57: 908-910.
79. Kiricuta IC, Willner J, Kolbl O, et al: The prognostic significance of the supraclavicular lymph node metastases in breast cancer patients. Int J Radial Oncol Biol Phys 1994;28:387-393.
80. Rosen PP, Groshen S, Saigo PE, et al: Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: A study of 644 patients with median follow-up of 18 years. J Clin Oncol 1989;7:1239-1251.
81. Ciatto S, Cecchini S, Iossa A, et al: Prognosis of nonpalpable infiltrating carcinoma of the breast. Surg Gynecol Obstet 1990;170:61-64.
82. Tinnemans JG, Wobbes T, Holland R, et al: Treatment and survival of female patients with nonpalpable breast carcinoma. Ann Surg 1989;209:249- 253.
83. Pagana TJ, Lubbe WJ, Schwartz SM. Sprechini GD: A comparison of palpable and nonpalpable breast cancers. Arch Surg 1989;124:26-28.
84. Tabar L, Duffy SW, Krusemo UB: Detection method, tumour size and node metastases in breast cancers diagnosed during a trial of breast cancer screening. Eur J Cancer Clin Oncol 1987;23:959-962.
85. Maehle BO. Skjaerven R: Prediction of prognosis in axillary lymph node positive breast cancer patients: A statistical study. Br J Surg 1984:71:459-462.
86. O'Reilly SM, Camplejohn RS, Barnes DM, et al: Node-negative breast cancer: Prognostic subgroups defined by tumor size and flow cytometry. J Clin Oncol 1990;8:2040-2046.
87. Merkel DE, Winchester DJ, Goldschmidt RA, et al: DNA flow cytometry and pathologic grading as prognostic guides in axillary lymph node-negative breast cancer. Cancer 1993;72:1926-1932.
88. Treatment of early stage breast cancer: NIH Concensus Development Conference. Consensus Statement 1990, June 18-21:8(6).
89. Alanko A, Heinonen E, Scheinin TM, et al: Oestrogen and progesterone receptors and disease-free interval in primary breast cancer. Br J Cancer 1984;50:667-672.
90. Shek LL, Godolphin W: Survival with breast cancer: The importance of estrogen receptor quantity. Eur J Cancer Clin Oncol 1989;25:243-250.
91. Hahnel R, Woodings T, Vivian AB: Prognostic value of estrogen receptors in primary breast cancer. Cancer 1979;44:671-675.
92. Baum M, Ebbs S, Brooks M, et al: Biological fallout from trials of adjuvant tamoxifen in early breast cancer, in Salmon SE (ed): Adjuvant Therapy of Cancer VI. Philadelphia, WB Saunders, 1990, pp 269-272.
93. Andry G, Suciu S, Pratola D, et al: Relation between estrogen receptor concentration and clinical and histological factors: Their relative prognostic importance after radical mastectomy for primary breast cancer. Eur J Cancer Clin Oncol 1989;25: 319-329.
94. Thorpe SM, Rose C: Oestrogen and progesterone receptor determinations in breast cancer: Technology and biology. Cancer Surv 1986;5:505-525.
95. Crowe JP, Gordon NH, Hubay CA, et al: The prognostic importance of estrogen receptor level for stage I breast cancer patients. Curr Probl Surg 1984;41:24-26.
96. McGuire WL: Prognostic factors in primary breast cancer. Cancer Surv 1986;5:527-536.
97. Stewart JF, Rubens RD, Millis RR, et al: Steroid receptors and prognosis in operable (stage I and II) breast cancer. Eur J Cancer Clin Oncol 1983;19: 1381-1387.
98. Holmes FA, Fritsche HA, Loewy JW, et al: Measurement of estrogen and progesterone receptors in human breast tumors: Enzyme immunoussay versus binding assay. J Clin Oncol 1990;8:1025-1035.
99. Marchetti E, Querzoli P, Moncharmont B, et al: Immunocytochemical demonstration of estrogen receptors by monoclonal antibodies in human breast cancer: correlation with estrogen receptor assay by dextran-coated charcoal method. Cancer Res 1987;47:2508-2513.
100. Bozzetti C, Naldi N, Guazzi A, et al: Determination of estrogen receptors in human breast cancer: Comparison between enzyme immunoassay and dextran-coated charcoal method. Tumori 1986;72:511-514.
101. McCarty KS Jr, Miller LS, Cox EB, et al: Estrogen receptor analyses: Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985;109:716-721.
102. Allred DC, Bustamante MA, Daniel CO, et al: Immunocytochemical analysis of estrogen receptors in human breast carcinomas: Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Arch Surg 1990;125:107-113.
103. Esteban JM, Felder B, Ahn C, et al: Prognostic-relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients. Cancer 1994;74:1575-1583.
104. Foekens JA, van Putten WLJ, Portengen H, et al: Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer. J Steroid Biochem Mol Biol 1990;37:815-821.
105. Predine J, Spyratos F, Prud'homme JF, et al: Enzyme-linked immunosorbent assay of pS2 in breast cancers, benign tumors, and normal breast tissues: Correlation with prognosis and adjuvant hormone therapy. Cancer 1992;69:2116-2123.
106. Ewers SB, Attewell R, Baldetorp B, et al: Prognostic potential of flow cytometric S-phase and ploidy prospectively determined in primary breast carcinomas. Breast Cancer Res Treat 1992;20:93-108.
107. Yuan J, Hennessy C, Corbett IP, et al: Node negative breast cancer: The prognostic value of DNA ploidy for long-term survival. Br J Surg 1991; 78:844-848.
108. Ghali VS, Liau S, Teplitz C, Prudente R: A comparative study of DNA ploidy in 115 fresh-frozen breast carcinomas by image analysis versus flow cytometry. Cancer 1992;70:2668-2672.
109. Hedley DW, Clark GM, Cornelisse CJ, et al: Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast: Report of the DNA Cytometry Consensus Conference. Cytometry 1993;14:482-485.
110. Lewis WE: Prognostic significance of flow cytometric DNA analysis in node-negative breast cancer patients. Cancer 1990;65:2315-2320.
111. Johnson H Jr. Masood S. Belluco C, et al: Prognostic factors in node-negative breast cancer. Arch Surg 1992;127:1386-1391.
112. Fisher B. Gunduz N, Costantino J, et al: DNA flow cytometric analysis of primary operable breast cancer: Relation of ploidy and S-phase fraction to outcome of patients in NSABP B-04. Cancer 1991;68:1465-1475.
113. Hedley DW, Rugg CA, Gelber RD: Association of DNA index and S-phase fraction with prognosis of nodes positive early breast cancer. Cancer Res 1987;47:4729-4735.
114. Olsxewski W, Darzynkiewicz Z, Rosen PP, et al: Flow cytometry of breast carcinoma. II. Relation of tumor cell cycle distribution to histology and estrogen receptor. Cancer 1981;48:985-988
115. Witzig TE, Ingle JN, Schaid DJ, et al: DNA ploidy and percent S-phase as prognostic factors in node-positive breast cancer: Results from patients enrolled in two prospective randomized trials. J Clin Oncol 1993;11:351-359.
116. Wenger CR, Beardslee S, Owens MA, et al: DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat 1993;28:9-20.
117. Bosari S, Lee AKC, Tahan SR, et al: DNA flow cytometric analysis and prognosis of axillary lymph node-negative breast carcinoma. Cancer 1992:70: 1943-1950.
118. Witzig TE, Gonchoroff NJ, Therncau T, et al: DNA content flow cytometry as a prognostic factor for node-positive breast cancer: The role ol multi-parameter ploidy analysis and specimen sonication. Cancer 1991;68:1781-1788.
119. Clark GM, Dressler LG, Owens MA, et al: Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 1989;320:627-633.
120. Clark GM, Mathieu M-C, Owens MA, et al: Prognostic significance of S-phase Iraction in good-risk, node-negative breast cancer patients. J Clin Oncol 1992;10:428-432.
121. Kute TE, Muss HB, Cooper MR, et al: The use of flow cytometry for the prognosis of stage II adjuvant treated breast cancer patients. Cancer 1990; 66:1810-1816.
122. Stal O, Dulmats M, Halschek T. el al: S-phase fraction is a prognostic factor in stage I breast carcinoma. J Clin Oncol 1993;11:1717-1722.
123. Sigurdsson H, Baldetorp B, Borg A, et al: Indicators of prognosis in node-negative breast cancer. N Engl J Med 1990;322:1045-1053.
124. Witzig TE, Ingle JN, Cha SS, et al: DNA ploidy and the percentage of cells in S-phase as prognostic factors for women with lymph node negative breast cancer. Cancer 1994;74:1752-1761.
125. Meyer JS: Cell kinetics of breast and breast tumors, in Donegan WL, Spratt JS (eds): Cancer of the Breast. Philadelphia, WB Saunders Co. 1995, pp 279-280.
126. Baak JPA, Van Dop H, Kurver PH, Hermans J: The value of murphometry to classic prognosticators in breast cancer. Cancer 1985;56:374-382.
127. Goodson WH 3rd. Ljung BM. Waldman F. et al: In vivo measurement of breast cancer growth rate. Arch Surg 1991;126:1220-1224.
128. Meyer JS, Province M: Proliferate index of breast carcinoma by thymidine labeling: Prognostic power independent of stage, estrogen and progesterone receptors. Breast Cancer Res Treat 1988; 12:191-204.
129. Goodson WH 3rd. Ljung B-M, Moore DH 2nd, et al: Tumor labeling indices of primary breast cancers and their regional lymph node metastases. Cancer 1993;71:3914-3919.
130. Meyer JS, Wittliff JL: Regional heterogeneity in breast carcinoma: Thymidine labelling index. steroid hormone receptors. DNA ploidy. Int J Cancer 1991;47:213-220.
131. Meser JS, Province MA: S-phase fraction and nuclear size in long term prognosis of patients with breast cancer. Cancer 1994;74:2287-2299.
132. Silvestrini R, Daidone MG, Di Fronzo G, et al: Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer. Brenst Cancer Res Treat 1986;7:161-169.
133. Gerdes J, Lemke H, Maisch H, et al: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal anti-body Ki-67. J Immunol 1984;133:1710-1715.
134. Grasparini G, Pozza F, Meli S, et al: Breast cancer cell kinetics: Immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness. Anticancer Res 1991;11:2015-2021.
135. Veronese SM, Gambacorta M, Gottardi O, et al: Proliferation index as a prognostic marker in breast cancer. Cancer 1993;71:3926-3931.
136. Railo M, Nordling S, Von Boguslawsky K. et al: Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer 1993; 68:579-583.
137. Vecchione A: New and old in prognosis determination. In Vivo 1993;7:623-626.
138. Pujol P, Maudelonde T, Daures JP, et al: A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol. Cancer 1993;71:2006-2012.
139. Isola J, Weitz S, Visakorpi T, et al: Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillar node-negative breast cancer. J Clin Oncol 1993;11:36-43.
140. Tandon AK, Clark GM, Chamness GC, et al: Cathepsin D and prognosis in breast cancer. N Engl J Med 1990;322:297-302.
141. Winslanley JH, Leinster SJ, Cooke TG, et al: Prognostic significance of cathepsin-D in patients with breast cancer. Br J Cancer 1993;67:767-772.
142. Stonelake PS, Baker PG, Gillespie WM: Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer. Eur J Cancer 1994;30A:5-11.
143. Seshadri R, Horstall DJ, Firgaira F, et al: The relative prognostic significance of total cathepsin D and HER-2/neu oncogene amplification in breast cancer: The South Australian Breast Cancer Study Group. Int J Cancer 1994;56:61-65.
144. Ravdin PM, Tandon AK, Allred DC, et al: Cathepsin D by western blotting and immunohistochemistry: Failure in confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol 1994;12:467-474.
145. Duffy MJ, Reilly D, McDermott E, et al: Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer 1994;74:2276-2280.
146. Marks JR, Humphrey PA, Wu K, et al: Overexpression of p53 and HER-2/neu proteins as prounostic markers in early stage breast cancer. Ann Surg 1994;219:332-341.
147. Pierce LJ, Merino MJ, D'Angelo Te, et al: Is cerb B-2 a predictor for recurrent disease in early staue breast cancer? Int J Radiat Oncol Biol Phys 1994;28:395-403.
148. Allred DC, Clark GM, Tandon AK, et al: HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992;10:599-605.
149. Press MF, Pike MC, Chazin VR, et al: Her-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerised image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993;53:4960-4970.
150. Gusterson BA, Gelber RD, Goldhirsch A, et al: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992;10:1049-1056.
151. Tetu B, Brisson J: Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer: The influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994;73:2359-2365.
152. Toikkanen S, Helin H, Isola J, Joensuu H: Prognostic significance of HER-2 oncoprotein expression in breast cancer: A 30-year follow-up. J Clin Oncol 1992;10:1044-1048.
153. Muss HB, Thor AD, Berry DA, et al: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-1266.
154. Hayes DF: Tumor markers for breast career. Ann Oncol 1993;330:1260-1266.
155. Leitzel K, Teramoto Y, Konrad K, et al: Elevated serum c-erb B-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995;13:1129-1135
156. Hurwitz M, Sawicki M, Samara G, Passaro E Jr: Diagnostic and prognostic molecular markers in cancer. Am J Surg 1992;164:299-306.
157. Leslie KO, Howard P: Oncogenes and antioncogenes in human breast carcinoma. Pathol Annu 1992;27:321-342.
158. Clair T, Miller WR, Cho-Chung YS: Prognostic significance of the expression of a ras protein with a molecular weight of 21,000 by human breast cancer. Cancer Res 1987;47:5290-5293.
159. Spandidos DA, Karaiossifidi H, Malliri A, et al: Expression of ras, Rb1, and p53 proteins in human breast cancer. Anticancer Res 1992;12:81-89.
160. Mansour EG, Ravdin PM, Dressler L: Prognostic factors in early breast carcinoma. Cancer 1994;74:381-400.
161. Isola J, Visakorpi T, Holli K, Kallioniemi OP: Association of overevpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 1992;84:1109-1114.
162. Thor AD, Moore DH II, Edgerton SM, et al: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84:845-855.
163. Friedrichs K, Gluba S, Eidtmann H, et al: Overexpression of p53 and prognosis in breast cancer. Cancer 1993;72:3641-3647.
164. Davidolf AM, Herndon JE 2nd. Glover NS, et al: Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery 1991;110:259-264.
165. Silvestrini R, Benini E, Daidone MG, et al: p53 as an independent prognostic marker m lymph node-negative breast cancer patients. J Natl Cancer Inst 1993;85:965-970.
166. Allred DC, Clark GM, Elledge R, et al: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85:200-206.
167. Levine MN, Browman GP, Gent M, et al: When is a prognostic factor useful? A guide for the perplexed. J Clin Oncol 1991;9:348-356.
168. Robert NJ: Biologic indicators of prognosis in breast cancer. Hosp Pract 1990;25:93-98,101-102.
169. Gasparini G, Pozza F, Harris AL: Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 1993;85:1206-1219.
170. McGuire WL, Clark GM: Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 1992;326:1756-1761.
171. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:1-15,71-85.
172. Treatment of early-stage breast cancer. NIH Consensus Development Conference Consensus Statement. June 18-21, 1990,8(6).
173. Glick JH, Gelber RD, Goldhirsch A, et al: Meeting highlights: Adjuvant therapy for primary breast cancer. J Natl Cancer Inst 1992;84:1479-1485.
174. Goldhirsch A, Wood WC, Senn H-J, et al: Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1995;87:1441-1445.